This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1997 Dec;11(6):490-6.

doi: 10.2165/00002512-199711060-00008.

Metrifonate

H M Lamb¹, D Faulds

Affiliations

PMID: 9413706
DOI: 10.2165/00002512-199711060-00008

Review

Metrifonate

H M Lamb et al. Drugs Aging. 1997 Dec.

. 1997 Dec;11(6):490-6.

doi: 10.2165/00002512-199711060-00008.

Authors

H M Lamb¹, D Faulds

Affiliation

¹ Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

PMID: 9413706
DOI: 10.2165/00002512-199711060-00008

No abstract available

PubMed Disclaimer

Similar articles

Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.
Pettigrew LC, Bieber F, Lettieri J, Wermeling DP, Schmitt FA, Tikhtman AJ, Ashford JW, Smith CD, Wekstein DR, Markesbery WR, Orazem J, Ruzicka BB, Mas J, Gulanski B. Pettigrew LC, et al. J Clin Pharmacol. 1998 Mar;38(3):236-45. doi: 10.1002/j.1552-4604.1998.tb04421.x. J Clin Pharmacol. 1998. PMID: 9549662 Clinical Trial.
Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
Knopman DS. Knopman DS. Neurology. 1998 May;50(5):1203-5. doi: 10.1212/wnl.50.5.1203. Neurology. 1998. PMID: 9595961 No abstract available.
Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.
Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Becker RE, et al. Alzheimer Dis Assoc Disord. 1998 Mar;12(1):54-7. doi: 10.1097/00002093-199803000-00009. Alzheimer Dis Assoc Disord. 1998. PMID: 9539412 Clinical Trial.
Metrifonate: a new agent for the treatment of Alzheimer's disease.
Williams BR. Williams BR. Am J Health Syst Pharm. 1999 Mar 1;56(5):427-32. doi: 10.1093/ajhp/56.5.427. Am J Health Syst Pharm. 1999. PMID: 10096702 Review.
Metrifonate: overview of safety and efficacy.
Cummings JL. Cummings JL. Pharmacotherapy. 1998 Mar-Apr;18(2 Pt 2):43-6; discussion 79-82. Pharmacotherapy. 1998. PMID: 9543464 Review.

See all similar articles

Cited by

Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly.
VanDenBerg CM, Kazmi Y, Jann MW. VanDenBerg CM, et al. Drugs Aging. 2000 Feb;16(2):123-38. doi: 10.2165/00002512-200016020-00004. Drugs Aging. 2000. PMID: 10755328 Review.
Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Nordberg A, Svensson AL. Nordberg A, et al. Drug Saf. 1998 Dec;19(6):465-80. doi: 10.2165/00002018-199819060-00004. Drug Saf. 1998. PMID: 9880090 Review.

References

1. Neurochem Res. 1995 Sep;20(9):1081-8 - PubMed
1. Am J Hematol. 1991 Aug;37(4):280-2 - PubMed
1. Methods Find Exp Clin Pharmacol. 1994 May;16(4):285-9 - PubMed
1. Eur J Pharmacol. 1997 Mar 12;322(1):1-9 - PubMed
1. Behav Pharmacol. 1996 Jan;7(1):56-64 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information